Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
GAITHERSBURG, Md., Sept. 08, 2016 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in Washington, D.C. OpGen CEO Evan Jones will lead a presentation titled “Harnessing the power of informatics and genomic analysis to provide complete MDRO solutions” on Thursday, September 8 at 3:05 p.m. ET.
OpGen will also host a roundtable discussion called “Antibiotic resistant bacteria in our Integrated Healthcare Network: are new diagnostic tests needed?” on Friday, September 9 from 1:40 p.m. to 2:20 p.m. ET. The roundtable will feature Bert Lopansri, M.D., Associate Professor of Medicine, University of Utah; Chief of Infectious Diseases, Intermountain Healthcare; and Medical Director, Urban Central Region Microbiology Lab, Division of Infectious Diseases and Epidemiology.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen Michael Farmer Director, Marketing (240) 813-1284 [email protected] [email protected] Investor Relations LHA Kim Sutton Golodetz (212) 838-3777 [email protected] or Bruce Voss (310) 691-7100 [email protected] OpGen Media MacDougall Biomedical Communications Cammy Duong 781-235-3060 [email protected]
